Biomarkers and Imaging in Upfront Metastatic Prostate Cancer Diagnosis

7 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
David Morris, MD, FACS, of Urology Associates of Nashville, moderates this roundtable discussion on the mHSPC and mCRPC treatment landscape, alongside an expert panel consisting of John Phillips, MD, of Tennessee Oncology; Jeremy McDuffie, MD, of Tennessee Oncology; Katy Beckermann, MD, PhD, of Vanderbilt University Medical Center; and Alan Tan, MD, of Vanderbilt University Medical Center.
In the first part of their conversation, the group tackles key topics in prostate cancer care, including advances in imaging, risk stratification, and multidisciplinary approaches to patient care. The panel shares insights on navigating high-volume vs. low-volume disease distinctions, the role of PSMA PET scans, and tailored treatment strategies in prostate cancer management.

#prostatecancer #prostatecarcinoma #oncology #medicaloncology #healthcare #cancer #cancerresearch
Category
Oncology
Be the first to comment

Up Next